New drug can help stop certain breast cancer tumours early, trial shows
A new drug can help stop certain breast cancer tumours before they grow, experts say.
A trial called Serena-6 shows that camizestrant stops cancer cells from using hormones to grow, which helps patients stay well longer and delays the need for chemotherapy.
It is the first worldwide study to show that using blood tests to find early signs of cancer resistance to treatment helps patients, scientists say.
The study looked at patients who had hormone-positive, HER2-negative breast cancer, which is about 70% of cases.
Results showed patients given camizestrant reduced their chances of cancer progression by 56%, compared with just standard therapies.
Doctors used a simple blood test to spot changes in the cancer's DNA that show whether current treatments might soon stop working.
When they found these signs, some patients were given camizestrant, while others stayed on their usual treatment.
Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others.
The drug was safe for most patients but 1% stopped taking it because of side effects.
More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London.
Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'.
Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.'
About 55,000 women are diagnosed with breast cancer in the UK every year and 11,500 will die from the disease, The Institute of Cancer Research said.
The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday.
Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment.
'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow.
'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions.
'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
3 hours ago
- Daily Mail
Sleep problem that affects 10million could trigger deadliest cancer - first major study to spot the link
Severe snorers may be at higher risk of one of Britain's deadliest cancer, shock new research has suggested. It is already known that patients with obstructive sleep apnoea (OSA), which often causes problem snoring, may be more likely to develop cancer. Now, one of the world's first trials exploring the condition and lung cancer specifically has found a 'significant' link between the two. US researchers, who assessed the health records of more than 2.4million adults, said they cannot be sure exactly why the common sleep disorder raises this risk. But they believe it may be due to the lack of oxygen people get during the night - or lifestyle factors including smoking and even obesity. Presenting the findings at the American Society of Clinical Oncology conference in Chicago, scientists urged policymakers to consider screening those with the condition for the disease and tackle sleep apnea early, soon after a diagnosis. OSA, which impacts nearly a billion people worldwide, causes the walls of the throat to relax and narrow or close for a few seconds during sleep. This triggers breathing pauses and loud snoring. Up to 3.9 million people in the UK are estimated to have moderate or severe OSA, although it is considered to be under-diagnosed affecting up to 10million. Not all snorers have sleep apnoea, but the two often go hand in hand, and the louder the snoring, the greater the chances of having it. In the study, researchers at Marshall University in West Virginia, tracked lung cancer diagnoses separating those diagnosed with OSA and those without. After accounting for factors that could skew the results, such as age and other diagnosed health conditions, they found OSA patients were 1.21 times more likely to develop lung cancer compared to those without OSA. Dr Jowan Al-Nusair, study co-author and physician at Marshall University told MailOnline it was 'one of the first statistically significant studies' to prove a link between the condition and lung cancer. 'While further studies are definitely now needed to investigate just how the significant the link truly is, this suggests OSA may be a preventable risk factor for lung cancer. 'We should be more closely monitoring patients with OSA. Patients would definitely benefit from screening and early intervention to combat OSA. 'Additional studies are essential to understand exactly why OSA may increase this risk. 'We really hope this will pave the way for future research and testing.' Lung cancer strikes around 50,000 people in the UK and 230,000 in the US every year. It is the world's biggest cancer killer. It is notoriously difficult to diagnose and often appears later when it's harder to treat. Figures show it kills four out of five patients within five years. Fewer than 10 per cent of people survive their disease for a decade or more. Despite the progress, a disparity among sexes is emerging, with women between the ages of 35 and 54 being diagnosed with lung cancer at higher rates than men in that same age group. Science has long established that smoking definitively causes lung cancer and is the primary risk factor for the disease. But lung cancer rates, which have been dropping for decades as the world weans off tobacco, are also now rising in young, otherwise healthy people who've never smoked. Experts told MailOnline the disease should not be viewed as 'an old person's disease' — as it was previously seen. Speaking at ASCO it was also suggested diet, changes in exercise habits and changes in work patterns could play a part in this increased risk. It comes as a study by The Sleep Charity last year found nine in ten people experience some sort of sleep problem. Poor sleep has been linked to a number of health problems, including cancer, stroke and infertility. Experts have long advised that waking up during the night does not necessarily mean you have insomnia, which figures suggest affects up to 14million Brits. Still, sleep deprivation takes its own toll, from irritability and reduced focus in the short term, to an increased risk of obesity, heart disease and diabetes.
The Independent
14 hours ago
- The Independent
‘Transformational' new breast cancer drug could halt the growth of tumours
A new drug has been shown to halt the growth of certain breast cancer tumours, potentially delaying the need for chemotherapy, according to a new study. The Serena-6 trial found that camizestrant is effective in stopping cancer cells from using hormones to grow. One professor described the drug as representing "a pivotal moment in breast cancer care". Scientists said the trial marked the first global study demonstrating that early detection of cancer resistance through blood tests can significantly benefit patients. The study focused on patients with hormone-positive, HER2-negative breast cancer, which accounts for approximately 70 per cent of all cases. The results indicated that patients treated with camizestrant experienced a 56 per cent reduction in cancer progression compared to those receiving standard therapies. Doctors used a blood test to identify changes in the cancer's DNA, which signal the potential failure of current treatments. Upon detecting these signs, some patients were administered camizestrant, while others continued with their standard treatment. Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others. The drug was safe for most patients but 1 per cent stopped taking it because of side effects. More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London. Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'. Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.' About 55,000 women are diagnosed with breast cancer in the UK every year and 11,500 will die from the disease, The Institute of Cancer Research said. The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday. Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment. 'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow. 'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions. 'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
Daily Mail
16 hours ago
- Daily Mail
Stop denying thousands of women with incurable breast cancer wonder drug that could boost survival almost 50%, NHS urged
A lifeline drug currently denied to thousands of women with incurable breast cancer could boost survival by almost 50 per cent, pivotal new research has suggested. Medics hailed the drug Enhertu after the trial showed it could extend the lives of patients with one of the hardest to treat forms of the disease, buying them an extra year or more of life. Campaigners said the new findings add to the 'betrayal' that they cannot get the life-extending treatment on the NHS in England or Wales when it is already available in Scotland. It follows repeated decisions by NHS spending watchdog the National Institute for Health and Care Excellence (NICE) to deny the 'wonder drug' on cost grounds using new criteria which does not class all terminal cancers as 'severe'. Also known as trastuzumab deruxtecan, it is a targeted treatment for patients with a an aggressive and fast-growing type of cancer, known as HER2-positive—accounting for roughly one in five cases of the disease. Researchers presenting the findings at the American Society of Clinical Oncology conference in Chicago said it showed Enhertu was a 'highly effective' drug that should become the first port of call for patients with this form of breast cancer. In the trial, women taking the drug alongside another treatment called pertuzumab, lived without their cancer growing for 40.7 months on average, compared to just 26.9 among those who took standard treatment—the drug trastuzumab and pertuzumab. Enhertu slashed the risk of death or the disease progressing by 44 per cent, they added. After two years, around 70 per cent of patients on the new combination had not seen their cancer grow or spread, compared to around 52 per cent on standard treatment. For those who had received the combination, 85 per cent saw their cancer shrink or disappear compared to 78.6 per cent in the standard treatment group. Dr Sara Tolaney, head of breast oncology at the Dana-Farber Cancer Institute in Boston and study lead author, said: 'This trial has the potential to establish a new first line treatment for advanced HER2-positive breast cancer, a setting which hasn't seen significant innovation in more than a decade. Trastuzumab deruxtecan is a 'highly effective' and 'promising' therapy, she added. Around 1,000 women each year in England could benefit from the drug, which patients described as 'the last roll of the dice'. Last year, after NICE prevented the drug from receiving NHS funding—a decision the charity Breast Cancer Now called 'a dark day for women with incurable breast cancer'—one 46-year-old patient told how Enhertu would give her more time with her seven-year-old daughter Grace. Former marketing professional, Kathryn Hulland, who lives in Devon, was diagnosed with breast cancer in 2020 and underwent chemotherapy and surgery to remove the tumour. She responded well, but at Christmas 2022 she found a lump on her neck and was told her cancer had returned and spread. Checking your breasts should be part of your monthly routine so you notice any unusual changes. Simply rub and feel from top to bottom, in semi-circles and in a circular motion around your breast tissue to identify any abnormalities She said: 'If my chemo stops working, there won't be many treatments left.' She added: 'Six months more with her would mean the world. It's heartbreaking that patients in Scotland can get it, but I can't. It's a lifeline I can't reach.' Following NICE's decision, in an unusual move the watchdog hit out at AstraZeneca, the British firm who manufactures Enhertu, accusing it of being 'unwilling to offer a fair price'. But the pharmaceutical giant said the drug—believed to cost about £120,000 a year per patient—was available in 18 other European countries, including Scotland. Breast cancer specialist and author Dr Liz O'Riordan told MailOnline today: 'This trial yet again shows the huge benefits Enhertu can offer women, giving them vital extra months and years. 'This postcode lottery is so unfair. It's a betrayal to patients in England and Wales that they cannot access Enhertu, when it is already available in Scotland. 'What more will it take for it to be approved.' Dr Catherine Elliott, director of research at Cancer Research UK, meanwhile told MailOnline: 'Treatments that target HER2-positive metastatic breast cancers have transformed outcomes for many people but most still see their cancer progress within two years of starting treatment. 'These trial results suggest that adding Enhertu to the standard treatment could prevent or slow the growth of this type of breast cancer beyond three years. 'Importantly, people given this treatment were also more likely to see their tumour shrink or disappear.'
